Time filter

Source Type

Sievers C.,Max Planck Institute of Psychiatry | Klotsche J.,TU Dresden | Pieper L.,TU Dresden | Schneider H.J.,Ludwig Maximilians University of Munich | And 6 more authors.
European Journal of Endocrinology | Year: 2010

Objective: Although associations between testosterone and cardiovascular (CV) morbidity in women have been proposed, no large prospective study has evaluated potential associations between testosterone and mortality in women. The objective was to determine whether baseline testosterone levels in women are associated with future overall or CV morbidity and mortality. Design: Prospective cohort study with a 4.5-year follow-up period. Methods: From a representative sample of German primary care practices, 2914 female patients between 18 and 75 years were analyzed for the main outcome measures: CV risk factors, CV diseases, and all-cause mortality. Results: At baseline, the study population was aged 57.96 ± 14.37 years with a mean body mass index of 26.71 ± 5.17 kg/m2. No predictive value of total testosterone for incident CV risk factors or CV diseases was observed in logistic regressions. Patients with total testosterone levels in the lowest quintile Q1, however, had a higher risk to die of any cause or to develop a CVevent within the follow-up period compared to patients in the collapsed quintiles Q2-Q5 in crude and adjusted Cox regression models (all-cause mortality: Q2-Q5 versus Q1: crude hazard ratios (HR) 0.49, 95% confidence interval (CI) 0.33-0.74; adjusted HR 0.62, 95% CI 0.42-0.939; CV events: Q2-Q5 versus Q1: crude HR 0.54, 95% CI 0.38-0.77; adjusted HR 0.68, 95% CI 0.48-0.97). Kaplan-Meier curves revealed similar data. Conclusions: Low baseline testosterone in women is associated with increased all-cause mortality and incident CV events independent of traditional risk factors. © 2010 European Society of Endocrinology.


Pilz S.,Medical University of Graz | Fahrleitner-Pammer A.,Medical University of Graz | Polt G.,Medical University of Graz | Grammer T.B.,Synlab Medizinisches Versorgungszentrum Heidelberg GmbH | And 4 more authors.
Klinikarzt | Year: 2010

Vitamin D deficiency is present in about 50% of the population worldwide, which is mainly a consequence of reduced sun exposure (ultraviolet-B radiation) of the skin, that is needed for dermal vitamin D production. Dietary intake of vitamin D is usually too low to maintain a sufficient vitamin D status. Over the last few years it was shown that most tissues and cells express the vitamin D receptor supporting the notion that vitamin D exerts various effects beyond its established role for maintenance of bone and skeletal health. Epidemiological data show that 25-hydroxyvitamin D levels, that are considered the best indicator of vitamin D status, are consistently associated with various diseases including cardiovascular, malignant and autoimmune diseases, but the causality of these associations, however, remains to be proven. Interventional trials are therefore urgently needed to elucidate whether vitamin D supplementation is useful for the prevention and/or treatment of various chronic diseases. Vitamin D supplementation has a great potential for the improvement of public health when considering the high prevalence of vitamin D deficiency and the easy, cheap and safe way by which vitamin D can be supplemented.


Friedrich N.,University of Greifswald | Schneider H.J.,Ludwig Maximilians University of Munich | Haring R.,University of Greifswald | Nauck M.,University of Greifswald | And 12 more authors.
Steroids | Year: 2012

Objective: Lower levels of anabolic hormones in older age are well documented. Several studies suggested that low insulin-like growth factor I (IGF-I) or testosterone levels were related to increased mortality. The aim of the present study was to investigate the combined influence of low IGF-I and low testosterone on all-cause mortality in men. Methods and results: From two German prospective cohort studies, the DETECT study and SHIP, 3942 men were available for analyses. During 21,838 person-years of follow-up, 8.4% (n = 330) of men died. Cox model analyses with age as timescale and adjusted for potential confounders revealed that men with levels below the 10th percentile of at least one hormone [hazard ratio (HR) 1.38 (95% confidence-interval (CI) 1.06-1.78), p = 0.02] and two hormones [HR 2.88 (95% CI 1.32-6.29), p < 0.01] showed a higher risk of all-cause mortality compared to men with non-low hormones. The associations became non-significant by using the 20th percentile as cut-off showing that the specificity increased with lower cut-offs for decreased hormone levels. The inclusion of both IGF-I and total testosterone in a mortality prediction model with common risk factors resulted in a significant integrated discrimination improvement of 0.5% (95% CI 0.3-0.7%, p = 0.03). Conclusions: Our results prove that multiple anabolic deficiencies have a higher impact on mortality than a single anabolic deficiency and suggest that assessment of more than one anabolic hormone as a biomarker improve the prediction of all-cause mortality. © 2011 Elsevier Inc. All rights reserved.


Siekmeier R.,Bundesinstitut For Arzneimittel Und Medizinprodukte Bfarm | Grammer T.B.,Synlab Medizinisches Versorgungszentrum Heidelberg GmbH | Scharnagl H.,Medical University of Graz | Stojakovic T.,Medical University of Graz | And 4 more authors.
LaboratoriumsMedizin | Year: 2010

Research completed during recent years has led to the notion that atherosclerosis is an inflammatory disease. Consequently, highly sensitive assays for C-reactive protein have been used to obtain additional information regarding an individual's cardiovascular risk. However, the measurement of lipoprotein-associated phospholipase A2, which specifically reflects the stability of the atherosclerotic plaque, the pathological correlate of atherosclerosis, has not yet been widely used. © 2010 by Walter de Gruyter Berlin New York.


Schneider H.J.,Ludwig Maximilians University of Munich | Friedrich N.,University of Greifswald | Klotsche J.,TU Dresden | Schipf S.,University of Greifswald | And 8 more authors.
European Journal of Endocrinology | Year: 2011

Objective: IGF1 is associated with metabolic parameters and involved in glucose metabolism. Low-IGF1 has been implicated in the etiology of glucose intolerance and subjects with pathological causes of either low- or high-IGF1 are at risk of diabetes. We hypothesized that both low- and high-IGF1 levels increase the risk of diabetes and aimed to assess the role of IGF1 in the risk of developing diabetes in a large prospective study. Design: An analysis of two prospective cohort studies, the DETECT study and SHIP. Methods: We measured IGF1 levels in 7777 nondiabetic subjects and assessed incident diabetes mellitus during follow-up. Results: There were 464 cases of incident diabetes during 32 229 person-years (time of follow-up in the DETECT study and SHIP: 4.5 and 5 years respectively). There was no heterogeneity between both studies (P>0.4). The hazard ratios (HRs) of incident diabetes in subjects with IGF1 levels below the 10th or above the 90th age- and sex-specific percentile, compared to subjects with intermediate IGF1 levels, were 1.44 (95% confidence interval (CI) 1.07-1.94) and 1.55 (95% CI 1.06-2.06) respectively, after multiple adjustment. After further adjustment for metabolic parameters, the HR for low-IGF1 became insignificant. Analysis of IGF1 quintiles revealed a U-shaped association of IGF1 with risk of diabetes. Results remained similar after exclusion of patients with onset of new diabetes within 1 year or with borderline glucose or HbA1c levels at baseline. Conclusions: Subjects with low- or high-IGF1 level are at increased risk of developing diabetes. © 2011 European Society of Endocrinology.


Ivandic B.,Synlab Medizinisches Versorgungszentrum Heidelberg GmbH | Ivandic B.,DIAneering Diagnostics Engineering and Research GmbH | Frey N.,Universitatsklinikum Schleswig Holstein
Hamostaseologie | Year: 2011

Inhibiting platelet function is a key therapeutic principle in cardiology because platelets play a pivotal role in triggering cardiovascular events. In addition to acetylsalicylic acid, a cyclooxygenase inhibitor, ADP-receptor blockers are frequently used for anti-platelet therapy. This therapy does not abolish platelet activation and aggregation. Platelets may still be activated by alternative routes such as the thrombin receptor-mediated pathway. New, more potent inhibitors of platelet function continue to lower the risk of ischaemic events but several trials and clinical registries have also shown that this advantage was frequently offset by an increased risk of bleeding complications. As a consequence, the individual risk of ischaemia and bleeding of a patient must be taken into consideration to select the platelet inhibitor offering the best benefit-risk ratio. Modern laboratory diagnostics may help to achieve this goal by complementing functional platelet tests with pharmacogenomic analyses consistent with the idea of "personalized medicine". © Schattauer 2011.


Patent
Synlab Medizinisches Versorgungszentrum Heidelberg GmbH | Date: 2011-02-10

The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the risk of mortality in a patient based on homoarginine and to reduce the risk of mortality by administration of homoarginine are disclosed. Moreover, the present invention relates to the use of homoarginine for the preparation of a medicament for the treatment of a patient having an increased risk of mortality caused by stroke or a cardiac cause. Furthermore, the present application relates to a pharmaceutical composition comprising homoarginine and a composition for foodstuff supplement comprising homoarginine.

Loading Synlab Medizinisches Versorgungszentrum Heidelberg GmbH collaborators
Loading Synlab Medizinisches Versorgungszentrum Heidelberg GmbH collaborators